The title compound, which differs from the powerful O-GlcNAcase (OGA) inhibitor GlcNAc-thiazoline only at the chalcogen atom (Se for S), is a much weaker inhibitor in a direct OGA assay. In human cells, however, the selenazoline shows comparable ability to induce hyper-O-GlcNAc-ylation, and the two show similar reduction of insulin-stimulated translocation of glucose transporter 4 in differentiated 3T3 adipocytes.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4210863 | PMC |
| http://dx.doi.org/10.1016/j.bmc.2010.08.010 | DOI Listing |
Publication Analysis
Top Keywords
oga inhibition
4
inhibition glcnac-selenazoline
4
glcnac-selenazoline title
4
title compound
4
compound differs
4
differs powerful
4
powerful o-glcnacase
4
o-glcnacase oga
4
oga inhibitor
4
inhibitor glcnac-thiazoline
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!